Background
Methods
Hospital setting and patients
Definitions
Statistical analysis
Results
Epidemiology
Total | AML | ALL | Lymphoma | CML/MPN | CLL | MM | MDS/AA |
p
| ||
---|---|---|---|---|---|---|---|---|---|---|
Number | 1962 | 606 | 160 | 769 | 60 | 27 | 197 | 143 | ||
Gender | Man | 1048 | 326 | 83 | 399 | 36 | 16 | 108 | 81 | 0.799 |
Woman | 914 | 280 | 77 | 370 | 24 | 11 | 89 | 62 | ||
Age, median(range), year | 55(15–97) | 54(17–92) | 38(16–86) | 57(15–97) | 48(18–86) | 61(37–89) | 59(30–87) | 55(17–94) | <0.001 | |
HBs Ag(+) at diagnosis | 286 | 75 | 13 | 142 | 6 | 5 | 31 | 14 | 0.002 | |
HBV reactivation | 97 | 29 | 3 | 46 | 1 | 2 | 10 | 6 | 0.335 | |
HBs Ag(−) positive seroconversion | 41 | 5 | 7 | 24 | 0 | 1 | 3 | 1 | 0.013 | |
Hepatitis C | 73 | 17 | 0 | 42 | 1 | 1 | 5 | 7 | 0.013 | |
Liver cirrhosis | 21 | 6 | 1 | 10 | 1 | 0 | 1 | 2 | 0.924 | |
Hepatocellular carcinoma | 9 | 3 | 0 | 4 | 2 | 0 | 0 | 0 | 0.038 | |
Underlying diabetes | 273 | 75 | 22 | 109 | 8 | 4 | 31 | 24 | 0.833 | |
Allogeneic transplantation | 439 | 233 | 81 | 48 | 18 | 2 | 3 | 54 | <0.001 |
Prophylaxis of hepatitis B reactivation in patients with hematological malignancy
Risk of HBV reactivation in HBV carrier
Factors | Reactivation N = 97 | No Reactivation N = 189 | Univariate P value | Multivariate P Value | Odds ratio(95% CI) |
---|---|---|---|---|---|
Hematological malignancy | 0.332 | NA | |||
AML | 29 | 46 | |||
ALL | 3 | 10 | |||
Lymphoma | 46 | 96 | |||
CML/MPN | 1 | 5 | |||
CLL | 2 | 3 | |||
Myeloma | 10 | 21 | |||
MDS/AA | 6 | 8 | |||
Age > 65 year | 0.052 | 0.198 | |||
Yes | 11 | 57 | |||
No | 86 | 132 | |||
Gender | 0.781 | NA | |||
Man | 55 | 106 | |||
Woman | 42 | 83 | |||
Hepatitis C | 0.180 | 0.453 | |||
Yes | 4 | 4 | |||
No | 93 | 185 | |||
Liver cirrhosis | 0.906 | NA | |||
Yes | 4 | 7 | |||
No | 93 | 182 | |||
Hepatocellular carcinoma | 0.032 | <0.001 | 0.101(0.029–0.355) | ||
Yes | 3 | 1 | |||
No | 94 | 188 | |||
Diabetes mellitus | 0.388 | NA | |||
Yes | 10 | 20 | |||
No | 87 | 169 | |||
Allogeneic transplantation | 0.113 | 0.269 | |||
Yes | 28 | 31 | |||
No | 69 | 158 | |||
Antiviral prophylaxis | <0.001 | <0.001 | 4.631(2.902–7.390) | ||
Yes | 26 | 145 | |||
No | 71 | 44 |
Risk factor of hepatitis B reverse seroconversion
Positive Sero- conversion (n = 41) | No conversion (n = 1635) | Univariate P value | Multivariate P value | Odds ratio (95% CI) | |
---|---|---|---|---|---|
Age | 0.174 | NA | |||
≧65 years | 12 | 466 | |||
< 65 years | 29 | 1169 | |||
Gender | 0.737 | NA | |||
Men | 22 | 866 | |||
Women | 19 | 769 | |||
Hematological malignancy | 0.038 | 0.084 | NA | ||
AML | 5 | 526 | |||
ALL | 7 | 140 | |||
Lymphoma | 24 | 603 | |||
CML/MPN | 0 | 54 | |||
CLL | 1 | 21 | |||
Myeloma | 3 | 163 | |||
MDS / AA | 1 | 128 | |||
Diabetes mellitus | 0.040 | 0.005 | 0.218(0.076–0.629) | ||
Yes | 10 | 233 | |||
No | 31 | 1402 | |||
Allogeneic transplantation | 0.116 | 0.013 | 0.182(0.047–0.701) | ||
Yes | 15 | 365 | |||
No | 26 | 1270 | |||
Liver cirrhosis | <0.001 | <0.001 | 0.002(0.000–0.047) | ||
Yes | 2 | 8 | |||
No | 39 | 1627 | |||
Hepatocellular carcinoma | 0.748 | NA | |||
Yes | 0 | 5 | |||
No | 41 | 1630 | |||
Hepatitis C | 0.216 | NA | |||
Yes | 0 | 65 | |||
No | 41 | 1570 | |||
Negative Anti-HBs Antibodya | 0.237 | NA | |||
Yes | 10 | 304 | |||
No | 24 | 1157 | |||
Low Anti-HBs Antibody a | 0.002 | 0.016 | 0.020(0.001–0.480) | ||
Yes | 30 | 915 | |||
No | 4 | 546 | |||
Positive Anti-HBc Antibodyb | 0.005 | 0.013 | 0.070(0.009–0.571) | ||
Yes | 18 | 567 | |||
No | 1 | 263 |